Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (S1): 47-50     DOI: 10.3909/ricm19S1S0006
Review Previous articles |
Access to PCSK9 Inhibitors
Seth J. Baum1, Norman E. Lepor2, Jennifer G. Robinson3
1 Preventive Cardiology, Inc., Boca Raton, FL
2 Cedars-Sinai Heart Institute, Los Angeles, CA
3 Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA
Download:  PDF(603KB)  ( 149 )
Export:  BibTeX | EndNote (RIS)      
Published:  20 January 2018     

Cite this article: 

Seth J. Baum, Norman E. Lepor, Jennifer G. Robinson. Access to PCSK9 Inhibitors. Reviews in Cardiovascular Medicine, 2018, 19(S1): 47-50.

URL: 

https://rcm.imrpress.com/EN/10.3909/ricm19S1S0006     OR     https://rcm.imrpress.com/EN/Y2018/V19/IS1/47

[1] Drash W. CNN Exclusive: California launches investigation following stunning admission by Aetna medical director. CNN website. https://www.cnn.com/ 2018/02/11/health/aetna-california-investigation/ index.html. Updated February 11, 2018. Accessed February 23, 2018.
[2] Hess GP, Natarajan P, Faridi KF, et al. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing. Circulation. 2017; 136: 2210-2219.
[3] Baum SJ, Toth PP, Underberg JA, et al. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017; 40: 243-254.
[4] Bendix J. Curing the prior authorization headache. Medical Economics website. http://medicaleconomics. modernmedicine.com/medical-economics/content/tags/americas-health-insurance-plans/curing-priorauthorization- headache. Published October 10, 2013; accessed February 22, 2018.
[5] Doshi JA, Puckett JT, Parmacek MS, Rader DJ. Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers. Circ Cardiovasc Qual Outcomes. 2018; 11: e003939.
[6] Value & access. National Forum for Heart Disease & Stroke Prevention website. https://www.nationalforum .org/collaborations/value-access-adherence/. Accessed February 23, 2018.
[7] Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015; 132: 2167-2192.
[8] Baum S. Cardiovascular risk in patients denied access to PCSK9i therapy. Presented at: American College of Cardiology Scientific Sessions: March 10-12, 2018; Orlando, FL.
No related articles found!
No Suggested Reading articles found!